Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban PK/PD in Nephrotic Syndrome
NCT04278729Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of apixaban in nephrotic syndrome (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Steady-state Area Under the Plasma Concentration Versus Time Curve From Time Zero to 12 Hours. Started Apr 2021; status: completed.
02
Drugs
apixaban
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT04278729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278729.